Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Huntington Ingalls Industries Inc (HII) Price & Performance

Adaptive Biotechnologies CorpTrade
Huntington Ingalls Industries IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Huntington Ingalls Industries Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Huntington Ingalls Industries Inc trades at $329.05 (market cap $12.92B). The key difference: Huntington Ingalls Industries Inc is far larger — about 3.2× Adaptive Biotechnologies Corp's market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTHII
Market Cap
$4.04B$12.92B
Sector
HealthTechnology
52-Week High
$25.45$453.73
52-Week Low
$12.30$265.40
Enterprise Value
$4.10B$15.84B
Dividend Yield
1.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Huntington Ingalls Industries Inc

HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII